[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"German University in Cairo\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":123},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,75,102],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100623256",false,"NCT07394270","Effect of Add-on L-Arginine Therapy on Heart Failure Patients","Effect of Add-on L-Arginine Therapy on Clinical Outcome of Heart Failure Patients: A Randomized- Controlled Trial","Inclusion Criteria:\n\n* Patients with EF \\\u003C40%\n* eGFR \\>30 mL\u002Fmin\u002F1.73 m2\n* Stable patients\n* Capable and willing to provide written consent\n\nExclusion Criteria:\n\n* Patients with implantable cardioverter-defibrillator\n* Pregnant or lactating fmeales\n* Patients with a history of sensitivity to L-Arginine or any of the excipients\n* Acute heart failure patients\n* Patients use L-arginine supplementation.\n* Patients with active herpes disease","ALL","19 Years",{"count":18,"type":19},200,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","Heart failure is considered one of the greatest challenges globally. There are various treatment strategies for heart failure. L-Arginine is an amino acid that was found to have beneficial effect on vasculature. This study aims to study the benefits and side effects of using L-arginine on the patients with ejection fraction \\\u003C40%",[25],"Heart Failure",[27,28,29,30,31],"Heart failure","Drug repurposing","L-Arginine","Add-on therapy","HFrEF","NOT_YET_RECRUITING","2026-02-01",{"date":35,"type":36},"2026-02-06","ACTUAL",{"date":38,"type":19},"2026-02",{"date":40,"type":19},"2027-07",{"name":42,"class":43},"German University in Cairo","OTHER",1,{"id":46,"slug":4,"hasResults":10,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":10,"sex":15,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":20,"phases":54,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":44},"100618981","NCT07338682","Evaluation of the Effect of L-Arginine on the Cognitive Function in Geriatric Patients","Evaluation of the Effect of L-Arginine on the Cognitive Function in Geriatric Patients, A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age \\>60 years\n* Montreal Cognitive Assessment (MoCA) test score from 10-25 (mild to moderate cognitive impairment)\n\nExclusion Criteria:\n\n* Presence of neurodegenerative diseases (e.g.: Alzheimer's disease, Parkinson's disease, Huntington's disease, Multiple Sclerosis)\n* Patients with history of L-arginine intolerance or allergy\n* Patients with asthma\n* Patients who recently had an acute myocardial infarction\n* Patients with history of stroke within 1 yaear\n* Patients who started or discontinued medications that may affect cognitive function (e.g., CNS psychotropics, antihistamines, or acetylcholinesterase inhibitors) during the study period.\n* Patients who initiated or stopped antihypertensive medications during the study period.\n* Patients who initiated or stopped antidiabetic medications during the study period.\n* Patients who initiated or stopped antihyperlipidemic medications during the study period.\n* Patients prescribed medications for depression, anxiety, or stress that may impact cognitive function\n* Patients on nitrates, phosphodiesterase-5 inhibitors, potassium sparing diuretics\n* Refusal to provide written informed consent","60 Years",{"count":53,"type":19},60,[22],"This study aims to evaluate the effect of L-arginine supplementation on cognitive function in geriatric patients. Eligible participants will receive either L-arginine (6 grams once daily) or placebo, and their cognitive performance will be assessed using validated cognitive assessment tools over the study period. The participants will receive the intervention for 4 weeks and followed up every 2 weeks. The primary outcome is improvement in cognitive function, while secondary outcomes include safety, tolerability, and quality of life measures. The findings may provide evidence for the potential role of L-arginine in supporting cognitive health in elderly populations.",[57,58],"Cognition Disorders in Old Age","Cognitive and Behavioral Impairment",[60,61,62,63,64,65],"L-arginine","Cognitive impairment","Geriatrics","Elderly","Cognitive Function","Nitric Oxide","RECRUITING","2026-01-18",{"date":69,"type":36},"2026-01-21",{"date":71,"type":36},"2025-08-27",{"date":73,"type":19},"2026-06-30",{"name":42,"class":43},{"id":76,"slug":4,"hasResults":10,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":10,"sex":15,"minAge":81,"maxAge":51,"enrollmentInfo":82,"targetDuration":4,"studyType":20,"phases":83,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":44},"100573998","NCT06753565","L-carnitine Supplementation in Rheumatoid Arthritis Patients","Effect of L-carnitine Supplementation on Disease Activity in Rheumatoid Arthritis Patients","Inclusion Criteria:\n\n* age between 18-60 years old\n* diagnosed of rheumatoid arthritis according to 2010 American College of Rheumatology\u002FEuropean League Against Rheumatism criteria for at least 6 months\n* enrolled patients treated with one of more of conventional DMARDs for ≥ 6 months with stable dose for ≥ 1 month before start of the study\n* active RA despite conventional DMARDs treatment (DAS28 ESR more than or equal 3.2)\n* patient or legal representative should sign informed consent\n\nExclusion Criteria:\n\n* pregnant or lactating female\n* patients with liver dysfunction (\\>1.5x the upper limit of normal value for ALT \\& AST)\n* Patients with kidney dysfunction (serum creatinine more than 1.2 mg\u002Fdl)\n* Patients with any active infection or concurrent malignancy\n* patients with uncontrolled medical conditions or other rheumatic diseases\n* patients currently taking drugs that could interact with carnitine like: warfarin","18 Years",{"count":53,"type":19},[22],"This study aims to evaluate the effect of l-carnitine as add- on therapy for improving the outcome in rheumatoid arthritis patients.",[86],"Rheumatoid Arthritis (RA)",[88,89,90,91,92,93],"Rheumatoid Arthritis","Carnitine","anti-inflammatory","anti-oxidant","ACR50%","disease activity","2025-01-04",{"date":96,"type":36},"2025-01-07",{"date":98,"type":36},"2024-12-31",{"date":100,"type":19},"2025-06",{"name":42,"class":43},{"id":103,"slug":4,"hasResults":10,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":10,"sex":15,"minAge":81,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":20,"phases":110,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100551330","NCT06458686","Effect of Vitamin D Supplementation on Mental Health: An Exploratory Study on A University Students Suffering From Vitamin D Deficiency","Inclusion Criteria:\n\n* For phase 1: sample will be selected using convenient sampling method where all students with an age range 18-22 years old fulfilling the eligibility criteria will be educated about the study protocol and will be asked to participate in the study.\n\nFor phase 2: students who diagnosed with deficient vitamin D level will be asked to participate in the study.\n\nExclusion Criteria:\n\n* Hypersensitivity to oral vitamin D supplements such as Diviton or Vidrop.\n\n  * Students taking medications affecting vitamin D metabolism such as anti-seizure medications: phenytoin, phenobarbital and carbamazepine, isotretinoin, steroids: dexamethasone, antibiotics: isoniazid and rifampin and antifungals: clotrimazole.\n  * Students taking antidepressants, drug for bipolar disorder treatment like lithium and antipsychotic agents like olanzapine.\n  * Students with insufficient vitamin D level (20-30 ng\u002FmL).\n  * Students with confirmed diagnosis with psychiatric illness.\n  * Students with a history of liver disease or dysfunction.\n  * Students with a history of kidney disease or dysfunction.","22 Years",{"count":109,"type":19},70,[111,22],"PHASE1","University students are susceptible to psychological burdens such as depressive symptoms, anxiety, and stress which might have been linked to vitamin D deficiency. Low serum vitamin D level is well recognized around the world. Vitamin D has been reported to modulate several neurological pathways in the brain that control psychological function. As a result, the purpose of this study is to evaluate the effect of vitamin D supplementation on the presence of depressive symptoms, anxiety, and stress in university students. The study will include two phases. The first phase is a cross-sectional phase assessing the prevalence vitamin D deficiency in addition to psychological symptoms. The second phase is a randomized controlled clinical trial that aims to assess the effect of vitamin D supplementation on the prevalent psychological symptoms and its impact on the academic performance among university students. The study will look at the relationship between mental health and vitamin D deficiency, as well as how it will affect academic performance of university students.",[114],"Psychiatric Disorder","2024-06-09",{"date":117,"type":36},"2024-06-13",{"date":119,"type":19},"2024-06-30",{"date":121,"type":19},"2026-09-30",{"name":42,"class":43},""]